Treatments
>
Immune-based therapies for
lymphomas
Last update: 11/18/2009 |
TOPICS
Vaccines
| Enhancing Vaccines | Rituxan & Other Monoclonal Antibodies | Other
| Review Articles
Vaccines and Other Immune-based therapies
Vaccine treatments are
investigational. The goal of this treatment is to induce an
immune response against tumor-specific antigens (proteins that only
exist on the tumor.) This is sometimes called active
immunity.
Vaccines:
TOPIC SEARCH: PubMed: Treatment
| Review |
Dendritic
| Idiotype
| DNA
type | Heat
Shock type
By site: ASCO
| ASH
| ClinicalTrials.gov
| Medscape
| Web
By authors: Bendandi
| Levy
| Timmerman
 | Idiotype
vaccines
|
| CD40L-transduced tumor cells as a vaccine
Briones, Timmerman, Levy
In vivo anti-tumor effect of CD40L-transduced tumor cells as a vaccine for
B-cell lymphoma.
Cancer Res. 2002 Jun 1;62(11):3195-9. PMID:
12036933 PubMed |
|
Cancer vaccines fact sheet
cancer.gov
|
|
Investigational
vaccine for cutaneous lymphomas: transgene.fr
| ClinicalTrials.gov
TG 1042's antitumoral activity relies on the
secretion of human IFNγ from tumor cells
adenovirally-transduced with the nucleotidic sequence encoding the
cytokine. IFNγ is a natural immunostimulant produced in the
body, whose antitumoral properties were demonstrated both in
animals and in humans.
...a high rate of local clinical responses : 55% of 31 evaluable
patients responded to the treatment with nine complete responses
(CR) and eight partial responses (PR). Out of the 26 patients with
cutaneous T-cell lymphoma (CTCL) 46% responded (six CR and six
PR), and 100% of the five patients with cutaneous B-cell lymphoma
(CBCL) responded to the TG1042 treatment (three CR and two PR) :
These results suggest that intralesional therapy with TG 1042
represents a non-toxic and effective treatment for CBCL.
|
|
Fusion-cell
vaccines: Patients' Cells From Tumors, The Immune
System Merged For Customized Cancer Therapy sciencedaily.com
/2004 | PubMed
Topic Search
|
|
Harvesting and handling tissue in preparation for
vaccines PAL
|
|
Heat
shock Protein vaccine - Safety and efficacy of heat
shock protein-peptide 96 complex (HSPPC-96)
in low-grade lymphoma. ASCO
|
|
Hybridoma Id Vaccine Results -
Overview - Biovest Cancer
Vaccine accentia.net
|
|
Treating cancer with vaccines
cancer.gov |
|
A New Vaccine Paradigm To
Break Tolerance
with Potential Applications for the Immunotherapy of B Cell
Lymphoma. Session Type: Poster Session 565-I ASH
2004 |
|
Trioma vaccines - potentially more potent, easier to make, and for more cancers
Related
PubMed Abstracts |
|
Viral
fusogenic membrane glycoproteins (FMG) related
abstracts | cancerres.aacrjournals.org |
Investigational approaches to enhance
vaccines:
(overcome tolerance and ways tumors escape)
| Can we
enhance cancer vaccines? Imatinib mesylate (STI-571)
enhances antigen-presenting cell function and overcomes
tumor-induced CD4+ T-cell tolerance. Blood. 2005 Feb
1;105(3):1135-43. Epub 2004 Sep 28. PMID:
15454486 | Related
articles
|
| Scientists
overcome immune resistance in dendritic cell vaccines for
cancer ~ 05 Apr 2004 medicalnewstoday.com
|
| anti-CTLA-4
- to optimize active immunity Related
abstracts
|
|
Boosting Mabs and vaccines? CpG-DNA activates dendritic cells
in vivo: T helper cell-independent cytotoxic T cell responses to
soluble proteins. Eur J Immunol. 2000 Dec;30(12):3591-7. Related
abstracts
|
| CPG-7909
(PF-3512676, ProMune®): toll-like receptor-9 agonist
in cancer therapy expertopin.com
Stimulation of toll-like receptor (TLR)9
activates human plasmacytoid dendritic cells and B cells, and
induces potent innate immune responses in preclinical tumor models
and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9
agonists that show promising results as vaccine adjuvants and in
the treatment of cancers, infections, asthma and allergy.
Related
studies: ClinicalTrials.gov
|
| Revlimid
(Lenalidomide) - for MDS
The mechanism of action is not yet fully
characterized. Lenalidomide possesses immunomodulatory
and antiangiogenic properties. It inhibited the secretion of
pro-inflammatory cytokines and increased the secretion of
anti-inflammatory cytokines from peripheral blood mononuclear
cells. ClinicalTrils.gov
|
| Adoptive
immunotherapy for indolent NHL and MCL using genetically
modified autologous
[from self] CD20-specific T cells
Of the 7 treated patients, 2 maintained a previous
complete response,
1 achieved a partial response, and 4 had stable
disease.
These results show the safety, feasibility, and
potential antitumor activity of adoptive T-cell therapy
using this approach. This trial was registered at Clinicaltrials.gov
NCT00012207
|
| Therapeutic
vaccination against murine lymphoma by intratumoral injection
of naive dendritic cells.
Cancer Res. 2005 Jul 1;65(13):5958-64. PMID:
15994975 | Related
articles
|
Rituxan and Other Monoclonal Antibodies
TOPIC
SEARCH: Antibodies
| Bispecific
Antibodies
Rituxan is an antibody that is thought
to have more than one mechanism of action, two of which are dependant
on immunity. These are ADCC and CDC which we describe
below. These immune mechanisms are referred to as passive
immunity:
Antibody-dependent cell-mediated cytotoxicity
(ADCC) - depends
on the presence of antibodies (Abs) that recognize a target cell (ADCC
specificity is therefore conferred by the specificity of the antibody).
Upon binding its antigen (Ag), the Antibody's Fc region is exposed and
will bind its receptor on the NK cell to form a bridge. Once the
bridge is formed, a poorly understood lytic (killing) signal is
delivered to the target cell, resulting in its demise. - (adapted from
the Merck Manual) Picture-it
Complement-dependent
cytotoxicity (CDC): A mechanism of killing cells in which
antibody bound to the target cell surface fixes complement, which
results in assembly of the membrane attack complex that punches holes
in the target cell membrane resulting in subsequent cell lysis. Picture-it
Other Immune-therapy directions
TOPIC
SEARCH PubMed: Adenovirus
| T-cell
Therapy | Bispecific
Antibodies
| Adenovirus:
Infects
lymph node cells isolated from patients with follicle lymphoma so that tumors express
proteins that make them more visible to immune cells.
|
|
Adoptive
immunotherapy (T-cell therapy)
"Scientists
are exploiting these observations to develop procedures that isolate
and expand to great numbers the immune cells responsible for this
effect [immune system ability to recognize cancer cells and destroy
them] so that the cells can be transfused into patients for cancer
treatment." 1
-
Adoptive Immunotherapy Fred
Hutch Cancer Center
-
Cancer T cell therapy expands
` Brian Becknell and
Michael A. Caligiuri Nature.com
Dec 2004 (subscription req.)
-
Safety of Cellular
Immunotherapy for CD19+ Follicular Lymphoma Using Autologous T
Cell Cytolytic Clones Genetically Modified to be CD19-Speific and
Express HyTK - City of Hope Medical Center centerwatch.com
-
NK cell adoptive immunotherapy - Andrea Velardi bloodjournal.org
In this issue of Blood, Miller and colleagues present data on the
administration of haploidentical NK cells to cancer patients. They
identify a feasible and safe method for in vivo NK cell expansion
and clinical efficacy.
-
T-cell therapy -
targeting cd20
A
Phase I Trial To Evaluate the Safety of Cellular
Immunotherapy using Genetically Modified Autologous
CD20-specific CD8+ T Cell Clones for Patients with Relapsed
CD20+ Indolent Lymphomas
The study of interest involves taking T-cells from
individual patients, genetically altering the cells so that
they
target CD20 (a receptor found on many b-cell lymphomas and
normal b-cells), expanding the numbers,
and re-infusing them into the patient following treatment
with CVP, a combination of chemotherapy agents.
-
T lymphocytes redirected against the kappa light
chain of human immunoglobulin efficiently kill mature B
lymphocyte-derived malignant cells. Blood. 2006 Dec
1;108(12):3890-7. Epub 2006 Aug 22.
PMID: 16926291 | Related
articles
-
T Lymphocyte Therapy of
Cancer PDF
"The aim of this article is to review the
possibilities, limitations and recent clinical experience with
this novel anticancer treatment, namely with adoptive
immunotherapy using antigen-specific T cells.
"
|
| Bisphosphonate therapy in multiple myeloma: past, present,
future.
Eur J Haematol. 2002 Nov-Dec;69(5-6):257-64. Review.
PMID: 12460229 | Abstracts
 |
Synthetic Phosphoantigens Enhance Human
V9V2 T Lymphocytes Killing of
Non-Hodgkin’s B Lymphoma molmed.org
(PDF)
|
|
|
Dipeptidyl
peptidase inhibitor (PT-100) ASCO
| Related
articles
An anti-tumor small molecule that amplifies immunity.
Trials running now looking at use with Rituxan.
|
| Cytokine
Therapy
|
Interferon-alpha
as immune modulation PAL
|
|
anti-CD20-IL2 immunocytokine is
highly efficacious in a SCID mouse model of established human B
lymphoma. Blood. 2005 Feb 3; PMID:
15692062
This preclinical work appears to be an engineered antibody that binds to cd20 (like rituxan),
modified to
interact with IL-2 (a cytokine firmly established as essential to t-cell
activation), and modified further to avoid being intercepted by t-cells
prior to binding to cd20 cells? Whatever. Amazing assembly.
|
|
| Identification
of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.
Int J Cancer. 2005 Jun 10;115(2):333-6. PMID:
15688394 | Related
articles
|
| Phase
II Clinical Trial of Interleukin-12 in Patients with
Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s
Disease aacrjournals.org
"The ability of recombinant human IL-12 therapy to
increase the number of circulating CD8+ cells and induce clinical
remissions in patients with relapsed NHL warrants further investigation
of the drug."
|
| Lenalidomide
- "The exact mechanism of the immunomodulatory drugs
(i.e. thalidomide, CC-4047/Actimid and lenalidomide) is not known.
Apart from interfering with the immune
system, they are also thought to act on angiogenesis."
wikipedia.org
| ClinicalTrials.gov
(Lenalidomide/ Revlimid)
TOPIC SEARCH: Mechanisms PubMed
Outcome ASCO
| Medscape |
PubMed
Safety ASCO
| PubMed
|
| Measles vaccine
Abstract
- PubMed
|
| PT-100, a small molecule dipeptidyl peptidase
inhibitor, has potent antitumor effects and augments
antibody-mediated cytotoxicity via a novel immune mechanism.
Cancer Res. 2004 Aug 1;64(15):5471-80. PMID:
15289357 | Related
articles
|
| Novel adoptive immunotherapy:
Cancer 'Cure' In Mice To Be Tested In Humans sciencedaily.com
| backgrounder
"Leukocyte Infusion Therapy" (LIFT) study
information and eligibility
|
Review Articles on Immune-based Therapies
|
IMMUNOTHERAPY AND CHEMOTHERAPY — A PRACTICAL PARTNERSHIP
PDF
|
|
The anticancer
immune response: indispensable for therapeutic success? http://bit.ly/4mm0rn
|
|
|
| ASH 2003 Update: Cellular Therapies and Vaccines for Hematologic Malignancies Conference Coverage
cancerconsultants.com
|
| Clinical Trials of Active Immunotherapy in NHL
lymphomafocus.org
John P. Leonard, MD - New York Presbyterian Hospital
Ronald Levy, MD - Professor of Medicine, Stanford University
Medical Center
David C. Fisher, MD - Instructor of Medicine, Dana-Farber Cancer
Institute, Harvard Medical School
|
|
|
| Immunotherapy of Non-Hodgkin's Lymphomas - Oliver
W. Press, John P. Leonard, Bertrand Coiffier, Ronald Levy and John
Timmerman HTM
|
| Monoclonal Antibody Therapy for Non-Hodgkin's
Lymphoma, Sledge Jr, MD, and Plante
Medscape
free login req.
|
|
Immunotherapy, Past Present and Future medscape
(free login req.)
|
|
Immunotherapy w/ autoBMT medscape
(free login req.)
|
|
Immunotherapy of malignant diseases: cancer therapy beyond
chemotherapy roche.com
PDF
Very nice primer on immunity and immunotherapy.
|
|
|
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+"Bispecific antibodies"+lymphoma+mechanism&btnG=Search){kind=link}
![ASCO](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.asco.org+"Bispecific antibodies"+lymphoma+outcome+response+){kind=link}
![Medscape](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.medscape.com+"Bispecific antibodies"+outcome+OR+response&btnG=Search){kind=link}
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+"Bispecific antibodies"+outcome+OR+response&btnG=Search){kind=link}
![ASCO](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.asco.org+"Bispecific antibodies"+safety+OR+toxicity){kind=link}
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+"Bispecific antibodies"+safety+OR+toxicity&btnG=Search){kind=link}
